157 related articles for article (PubMed ID: 3827603)
1. [Comparison of bioavailability and pharmacokinetic profiles between Theodur and a new sustained-release theophylline formulation].
Morishita M; Nagai T; Ishizaki T; Suganuma T; Kushida K; Minegishi A
Arerugi; 1986 Nov; 35(11):1099-104. PubMed ID: 3827603
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic characteristics of a new sustained-release theophylline capsule with a longer absorption profile: single and multiple dosing bioavailability studies.
Saccar CL; Green LD; Helsel CL; Niehls ME; Diconcetto JA; Mansmann HC; McGeady SJ
Ann Allergy; 1983 Apr; 50(4):245-8. PubMed ID: 6340563
[No Abstract] [Full Text] [Related]
3. [Comparative bioavailability of 2 oral theophylline sustained-release preparations].
Tritthart W; Lücker PW; Fáy E; Buchebner J
Arzneimittelforschung; 1983; 33(11):1603-6. PubMed ID: 6686457
[TBL] [Abstract][Full Text] [Related]
4. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
6. Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics.
Miyazaki Y; Yakou S; Takayama K
J Pharm Pharmacol; 2008 Jun; 60(6):693-8. PubMed ID: 18498704
[TBL] [Abstract][Full Text] [Related]
7. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of sustained-release theophylline formulations.
Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
[TBL] [Abstract][Full Text] [Related]
9. Theophylline bioavailability following oral administration of six sustained-release preparations.
Spangler DL; Kalof DD; Bloom FL; Wittig HJ
Ann Allergy; 1978 Jan; 40(1):6-11. PubMed ID: 623398
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic properties of a new sustained-release theophylline preparation.
Dahlqvist R; Billing B
Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
[TBL] [Abstract][Full Text] [Related]
11. Absorption of theophylline from conventional and sustained-release tablets.
Fagerström PO; Mellstrand T; Svedmyr N
Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels.
van der Vet AP; Drost RH; Kreukniet J; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):423-9. PubMed ID: 6490224
[TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of a delayed-action aminophylline preparation].
Regazzi MB; Guarnone E; Bartoli A; Ciardelli L; Piacentini P
Minerva Med; 1985 Mar; 76(13):641-5. PubMed ID: 3991030
[TBL] [Abstract][Full Text] [Related]
14. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
[TBL] [Abstract][Full Text] [Related]
15. [Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)].
Wiessmann KJ
Arzneimittelforschung; 1980; 30(2):329-32. PubMed ID: 7378114
[TBL] [Abstract][Full Text] [Related]
16. Deconvolution at steady state: determination of gastrointestinal bioavailability of sustained release theophylline.
Veng-Pedersen P; Miller R
Int J Clin Pharmacol Ther Toxicol; 1987 May; 25(5):233-7. PubMed ID: 3596848
[TBL] [Abstract][Full Text] [Related]
17. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects.
Bialer M; Salame K; Raz I
Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):662-7. PubMed ID: 4093206
[TBL] [Abstract][Full Text] [Related]
18. A comparison of steady state plasma theophylline concentrations with conventional and sustained release formulations.
Mellstrand T; Svedmyr K; Svedmyr N
Eur J Respir Dis; 1982 Jan; 63(1):31-4. PubMed ID: 7040098
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of whole and half Theo-Dur tablets.
Fagerström PO
Eur J Respir Dis Suppl; 1980; 109():62-6. PubMed ID: 6934089
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
Valet SB; Schwartz RH; Brooks JG
Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
